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Hit-to-leadThe treatment of neurodegenerative diseases is difﬁcult because of multiple etiologies and the interplay
of genetics and environment as precipitating factors. In the case of amyotrophic lateral sclerosis (ALS), we
have knowledge of a handful of genes that cause disease when mutated. However, drugs to counteract
the effect of genetic mutations have not yet been found. One of the causative genes, Cu, Zn-superoxide
dismutase (SOD1) is responsible for about 10–15% of the genetically linked autosomal dominant disease.
Our rationale was that compounds that reduce expression of the mutant protein would be beneﬁcial to
slow onset and/or disease progression. We screened candidate compounds using a cell-based in vitro
assay for those that reduce mutant SOD1 (G93A) protein expression. This led to the discovery of
2-[3-iodophenyl)methylsulfanyl]-5pyridin-4-yl-1,3,4-oxadiazole, a known protein kinase inhibitor that
decreases G93A-SOD1 expression in vitro and in the brain and spinal cord in vivo. However, this
compound has a biphasic dose response curve and a likely toxophore which limit its therapeutic window
for chronic disease such as ALS. Therefore, we designed and tested a focused library of analogs for their
ability to decrease SOD1 expression in vitro. This exercise resulted in the identiﬁcation of a lead
compound with improved drug-like characteristics and activity. Development of small molecules that
reduce the expression of etiologically relevant toxic proteins is a strategy that may also be extended to
familial ALS linked to gain of function mutations in other genes.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Amyotrophic lateral sclerosis (ALS) is etiologically heteroge-
neous and in ten percent of cases the disease is inherited as a
dominant, recessive or X-linked dominant trait, (familial ALS or
FALS). The other 90 percent of cases have no identiﬁable history
of familial disease and are called sporadic ALS or SALS. We and
others have identiﬁed mutations in ﬁve genes that cause ALS.
Mutations in these genes, SOD1,1 TDP-43(TARBP),2,3 FUS,4,5
optineurin (OPTN),6 Ubiquilin 2 (UBQLN2),7 and C9ORF728,9 cause
the formation of aggregates in motor neurons of the spinal cord.
Of interest is the fact that TDP-43, FUS, optineurin, p-62 (SQSTM1),and ubiquilin2 are also found in inclusions in the motor neurons of
SALS patients in the absence of mutations in the genes for these
proteins.7,10–12 Wild-type SOD1 has been reported to be present
within SALS cases with Lewy-body like inclusions13,14 and recent
reports using SOD1 aggregate speciﬁc antibodies have detected
aggregated SOD1 in SALS cases15,16 and in the cerebrospinal ﬂuid
of some ALS patients.17 One path for induction of wild-type SOD1
aggregates is through deamidation of asparagines residues.18
There is genetic proof of principle in SOD1-linked ALS that onset
is directly inﬂuenced by the level of the mutant protein. Manipula-
tion of SOD1 expression by gene dosage,19 siRNA,20 and neuron
speciﬁc knockdown21 is directly correlated with disease onset
in vivo. Previous high-throughput screening of compound libraries
for compounds that reduce SOD1 expression in cultured cells
yielded compounds that were generally too toxic to use in animal
studies.22 Our current work describes the efforts of many years
leading to discovery of a new class of compounds that reduce
SOD1 expression in ﬁbroblasts from transgenic mice expressing a
mutant SOD1 and exhibit favorable pharmacokinetics with respect
Figure 1. Chemical structures of the commercially available compounds tested in the in vitro assays for their ability to inhibit SOD1.
Figure 2. Inhibition of SOD1 protein expression in ﬁbroblasts from G93A-SOD1 mice. Fibroblasts were treated with the title compounds at the indicated concentration for
48 h. Cells were washed, lysed, and SOD1 levels measured by ELISA. SOD1 levels are normalized to the total protein in the lysate.
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class of small molecules that may be useful for treating SOD1-FALS
and ALS where SOD1 may be involved.
Small molecule inhibitors of SOD1 expression
Accumulated evidence suggests that inhibition of glycogen syn-
thase kinase III (GSK3b) might be beneﬁcial to survival of the mu-
tant SOD1 transgenic mouse23–25 however, SOD1 levels were not
evaluated in those studies. Thus, we used cultured ﬁbroblasts from
the G93A-SOD1 transgenic mouse to screen GSK3b protein kinase
inhibitors (Fig. 1) for their effects on SOD1 expression. The trans-
gene construct contains the human SOD1 promoter so that cellular
signaling processes that affect transcription of the gene will be
fully functional. We chose a structurally diverse group of com-Table 1
Published GSK3b inhibitors and measured SOD1 expression





1 GSK3B-IX 5b Increases SOD1 Also inhibits CDK5,CDK2, CDK1
2 GSK3B-XI 25b 10,000 Also inhibits CDK4
3 Kenpaullone 23c 10,000 Also inhibits CDK5,CDK2, CDK1
4 GSK3B-VI 1000d 650 Covalent binding inhibitor
5 Aloisine 650e Increases SOD1 Also inhibits CDK5, CDK1
6 SB216763 9f 3000 Active against GSK3B in vivog
7 GSK3B-II 390a 625
A Ref. 35.






Figure 3. Inhibition of SOD1 protein and mRNA expression by GSK3B-II in G93A-
SOD1 mouse ﬁbroblasts. (A) Dose-dependent changes in G93A-SOD1 protein
expression and (B) SOD1 mRNA (n = 3). Data are normalized to GAPDH activity
(protein) or mRNA. Error bars are SEM.pounds including some natural products. Figure 2 summarizes
the results from six of the commercially available compounds. (Cell
preparation and assay methods are in the Supplementary ﬁle). Two
compounds (Aloisine A and GSK3B-IX) increased SOD1 expression,
while several compounds inhibited at lower concentrations but
reversed at higher concentrations yielding a biphasic pattern.
Among these compounds, GSK3B-II was the most potent at inhib-
iting G93A-SOD1 expression (Fig. 3A). The IC50 values for GSK3b
kinase inhibition from the literature compared to SOD1 expression
are in shown in Table 1. GSK3B-VI also inhibits SOD1 expression
but this compound covalently modiﬁes GSK3b kinase at the active
site26 and exhibits cell toxicity at concentrations greater than 5 lM
making it a poor therapeutic candidate. Kenpaullone, one of the
more potent GSK3b inhibitors (Table 1), only weakly decreased
SOD1 expression. Thus, the disconnect between potencies of
GSK3b inhibitors and their effect on SOD1 expression suggests that
inhibition of GSK3b may not be the primary mechanism for
decreasing G93A-SOD1 expression in cultured ﬁbroblasts, although
other explanations such as differences in cell permeability cannot
be ruled out. We also determined that the decrease of SOD1
expression by GSK3B-II is primarily due to reducing the level of
SOD1 mRNA (Fig. 3B). Thus, GSK3B-II affects cellular processes that
lead to a decrease in the production of SOD1 mRNA and protein.
While GSK3B-II is a potentially useful molecular probe to study
the effects of reducing SOD1 expression, the compound exhibits a
biphasic dose–response curve and contains a potential toxophore
(Aryl-Iodo) which reduces its therapeutic potential. Hit-to-lead
medicinal chemistry was undertaken to quickly expand the SAR
and develop more drug-like inhibitors, especially ones without
the aryl iodide group. Modiﬁcations to previously reported condi-
tions27,28 were used to synthesize new 1,3,4-oxadiazole analogs
as shown in Scheme 1. Commercially available ethyl isonicotinate
was reﬂuxed with hydrazine hydrate for 1 h at 60 C and the
solvent was evaporated. Trituration of this solid with diethyl ether
afforded pure hydrazide 2 in 86% yield. The treatment of hydrazide
2 with CS2 and KOH in 60 C for 18 h produced a solid upon con-
centration in vacuo. It was found that this material could be easily
puriﬁed by trituration with H2O followed by ﬁltration to give thiol
3 in 78% yield, thus avoiding chromatography over the ﬁrst two
steps. This operationally simple procedure afforded multi-gram
quantities of 3 for subsequence focused library synthesis. Finally,
diversiﬁcation of the aryl ring was achieved by nucleophilic
displacement reaction of thiol 3 with substituted aryl bromides
in room temperature DMF using K2CO3 as base. The ﬁnal com-
pounds (4) were produced in yields of between 24% and 74%
depending on the aromatic ring substituent. All ﬁnal compounds
were judged to be consistent with desired product by 1H NMR
spectroscopy and had >95% purity as observed by liquid chroma-
tography–mass spectrometry analysis.
Structure–activity relationships (SAR) were developed using
mono aryl substituents on the benzyl ring (Table 2) to probe theScheme 1. Synthesis of 1,3,4-oxadiazole compounds. (a) hydrazine–H2O, EtOH,
reﬂux, 1 h; (b) CS2, KOH, EtOH, 60 C, 18 h; (c) K2CO3, Aryl-Br, DMF, rt, 2 h.
Table 2







a Sigmab Sigma+b Relative SOD1 expression 10 lM compound (p-value)c
7 (GSK3B-II) R = 3-Iodo 2.91 0.352 0.359 0.73 (0.022)
NUCC-433 R = 3-Methoxy 1.71 0.268 0.047 0.50 (0.005)
NUCC-319 R = 3-Fluoro 1.93 0.337 0.352 1.43 (0.001)
NUCC-435 R = 4-Triﬂuoromethyl 2.82 0.54 0.612 1.57 (0.003)
NUCC-439 R = 3-Chloro 2.51 0.373 0.399 0.96
NUCC-432 R = 3-Nitro 1.53 0.71 0.674 1.17
NUCC-318 R = 3-Bromo 2.65 0.391 0.405 0.91
NUCC-434 R = 4-Methoxy 1.71 0.115 0.778 0.47 (0.001)
NUCC-440 R = 4-Chloro 2.51 0.227 0.114 1.23 (0.09)
NUCC-320 R = 4-Bromo 2.65 0.232 0.15 1.03
NUCC-321 R = 4-Iodo 2.91 0.18 0.135 0.69 (0.026)
NUCC-324 R = 4-Fluoro 1.93 0.062 0.073 0.86
NUCC-436 R = 4-Methyl 2.29 0.17 0.311 1.26
NUCC-431 R = 4-Nitro 1.53 0.778 0.79 1.02
NUCC-441 R = H 2.29 NA 0 1.33 (0.07)
a C logP was calculated using ChemBioOfﬁce-ChemDraw V13.
b From Ref. 30.
c If not shown.
Figure 4. Inhibition of SOD1 expression in mouse ﬁbroblasts by NUCC-433 and
NUCC-434. (A) Dose–response curve for NUCC-434 and (B) NUCC-433. Note the
decrease in upward curvature of both compounds at 10 lM. Error bars are SEM.
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modiﬁcations were found to have a signiﬁcant effect on the
compounds’ ability to reduce SOD1 expression. The two best com-
pounds had methoxy substituents at the 3-position (NUCC-433) or
4-position (NUCC-434) and signiﬁcantly reduced the level of SOD1
expression to 47–50% of control at 10 lM. Some compounds such
as NUCC-319 (4-ﬂuoro) and NUCC-435 (4-triﬂuromethyl) actually
showed a signiﬁcant increase in SOD1 expression, conﬁrming the
importance of the aryl ring in functional activity. The unsubstitut-
ed benzyl ring (NUCC-441) activates expression of SOD1 while
other substituents (chloro, nitro, bromo, methyl) at the 3 or 4 posi-
tion of the ring were comparable to control in SOD1 expression.
Interestingly, there is a trend where electron withdrawing substit-
uents tended to cause an increase in SOD1 expression (NUCC-319,
435, 432, 440), while electron donating groups tended to produce
the largest SOD1 reduction (NUCC-433 and 434). Dose–response
relationships were determined for NUCC-433 and 434 as shown
in Figure 4. Unlike GSK3B-II (Fig. 3A), both compounds exhibit a
ﬂattened rather than upward curvature at higher concentration A
number of other analogs were synthesized and tested which had
variations in the pyridine portion of the molecule, including the
3-hydroxyl-, 3-amino-4-pyridyl, 3-pyridyl, and fused ring system
derivatives. All of these compounds with the exception of NUCC-
322 (3-pyridyl) showed either no effect on SOD1 expression or
slight increases.
We sought to quantify compound behavior by Hansch
analysis29 using C logP and the sigma or sigma+ values for meta
and para groups derived by Hammett.30 Sigma values are based
upon the ionization of substituted benzoic acids, while the sigma+
values are based upon the solvolysis of substituted 2-phenyl-2-
propyl chlorides.30 Three equations were tested for correlation of
the activity data with compound parameters.
1=ðrelSOD1Þ ¼ C log P þ sigmaþ sigmaþ ð1Þ
1=ðrelSOD1Þ ¼ C log P þ sigmaþ ð2Þ
1=ðrelSOD1Þ ¼ C log P þ sigma ð3Þ
Using the ‘systemﬁt’31 package in R (http://www.R-project.org/)
the coefﬁcients for the variables were calculated by solving simul-
taneous equations (Ordinary Least Squares). The best ﬁt (r2 = 0.58)was to Eq. 1 and Eq. 2 (r2 = .55). The coefﬁcients for Eq. 1 are:
1/relSOD1 = (0.1667)C logP + (0.2331)sigma + (0.4906))sigma+
+ 1.684. A plot of the predicted and experimental values is shown
in Figure. 5. The sole outlier was NUCC-436 based upon Grubbs test
(http://www.graphpad.com). Alternate analysis using Q values
(sum of squares of the residuals) gave comparable results.
One test of the speciﬁcity of the correlation was from testing of
NUCC-322 (Fig. 6), an isomer of the 4-bromo compound (NUCC-
320). While NUCC-320 showed no effect on SOD1 expression,
NUCC-322 inhibited SOD1 expression to 68.6% of control at
10 lM (p = 0.015). This suggests that both ends of the structure
contribute to target binding. Relatedly, NUCC-437 and NUCC-438
Figure 5. Plot of predicted versus experimental data for the inhibition of SOD1
expression by 1,3,4-oxadiazole compounds .The linear regression line was calcu-
lated using GraphPad Prism.
Table 3
Distribution of GSK3B-II in mouse tissues after a 20 mg/kg injection (n = 2)
Tissue Time Concentration (lM)
Brain 1 h 0.944
Spinal Cord 1 h 4.00
Serum 1 h 0.672
Brain 24 h 0.077
Spinal cord 24 h 0.855
Serum 24 h 0.073
Table 4
Distribution of CMIDD-434 in mouse tissues after a 10 mg/kg injection (n = 2)
Time (h) Serum (lM) Spinal cord (lM) Brain (lM)
2 0.153 0.057 0.029
4 0.334 0.162 0.047
24 0.123 0.113 ND*
* ND = Not detected.
Figure 7. Inhibition of SOD1 protein expression in the G93A-SOD1 mouse. GSK3B-I
treatment was at 20 mg/kg IP every other day for 26 days. Mice were sacriﬁced and
SOD1 measured in the indicated tissues. The change in expression was signiﬁcant
(⁄ = p <0.05, ⁄⁄⁄ = p <0.001) in all tested tissues (n = 20). Error bars are SEM.
Figure 6. Structures of related 1,3,4-oxadiazole analogs.
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activity (at 10 lM) not signiﬁcantly different from control indicat-
ing a target preference for benzyl groups.
The blood brain barrier permeability of GSK3B-II was deter-
mined in nontransgenic mice. At 20 mg/kg (intraperitoneal), the
compound rapidly distributes into the brain and spinal cord. This
compound is also long-lived in the CNS, with drug still detectable
after 24 h in the brain and spinal cord (Table 3). The peak and
sustained concentrations found in the spinal cord and brain indi-
cate that the 20 mg/kg dose puts the drug into the inhibitory range
found in the cellular assays.
We also tested compound NUCC-434 for distribution in non-
transgenic mice. However, the solubility of this compound was
poor in the standard 1–2% DMSO vehicle that we used for GSKB-
II. While there are a multitude of methods for improving aqueous
solubility of drugs32 we chose a relatively simple route using a
cyclodextrin based carrier (Sulfo-butylether beta-cyclodextrin,
Captisol) to solubilize the drug in aqueous solution. Using the cyclo-
dextrin carrier, we were able to solubilize NUCC-434 to 2 mg/mL in
water and deliver 10 mg/kg to nontransgenic mice for pharmacoki-
netics. Like GSK3B-II the compound entered the CNS and persisted
for 24 h in the spinal cord. However, the distribution dynamics are
different in the presence of the cyclodextrin which appears to slow
uptake into the CNS as the peak drug concentration was delayed(Table 4). Such changes in distribution dynamics using cyclodex-
trins have not been studied in detail.
As a proof of concept study, compound GSK3B-II was evaluated
in vivo for its ability to reduce levels of SOD1 in vivo. Initial testing
was carried out in a small cohort (5–6 animals) of G93A-SOD1mice
(high level of mutant SOD1 expression). The drug was dosed at
20 mg/kg IP every other day for 26 days. Mice were sacriﬁced
and SOD1 was measured by ELISA. In all tissues sampled: spinal
cord, cerebellum, brain stem, and cerebral cortex, signiﬁcant
decreases in SOD1 were measured (Fig. 7).
Conclusions
Compounds GSK3B-II, NUCC-433, and NUCC-434 are the ﬁrst
small molecules to exhibit dose dependent reduction of SOD1
expression in vitro and in the G93A-SOD1 mouse in vivo (GSK3B-
II) Compared to antisense oligonucleotides33 and the APC analog,34
we found a comparable decrease of SOD1 protein in cultured cells
with the new 1,3,4-oxdiazole analogs reported here. Thus, these
and related compounds may offer an opportunity to develop a
small molecule based ALS therapy.
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